CA2998665A1 - Improvement of expression and folding in the manufacturing process of cd-rap by using a cd-rap precursor protein - Google Patents

Improvement of expression and folding in the manufacturing process of cd-rap by using a cd-rap precursor protein Download PDF

Info

Publication number
CA2998665A1
CA2998665A1 CA2998665A CA2998665A CA2998665A1 CA 2998665 A1 CA2998665 A1 CA 2998665A1 CA 2998665 A CA2998665 A CA 2998665A CA 2998665 A CA2998665 A CA 2998665A CA 2998665 A1 CA2998665 A1 CA 2998665A1
Authority
CA
Canada
Prior art keywords
rap
composition
particular embodiments
protein
buffer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2998665A
Other languages
English (en)
French (fr)
Inventor
Isabell Schoettle
Judith STOMMES
Ursula STILLGER
Eckart Bartnik
Volker Jeske
Joachim SAAS
Paul Habermann (Deceased)
Bernd Janocha
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bionet Pharma GmbH
Original Assignee
Bionet Pharma GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bionet Pharma GmbH filed Critical Bionet Pharma GmbH
Publication of CA2998665A1 publication Critical patent/CA2998665A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
CA2998665A 2015-09-18 2016-09-16 Improvement of expression and folding in the manufacturing process of cd-rap by using a cd-rap precursor protein Abandoned CA2998665A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP15306458 2015-09-18
EP15306458.9 2015-09-18
EP15306457 2015-09-18
EP15306457.1 2015-09-18
EP15306950.5 2015-12-07
EP15306950 2015-12-07
PCT/EP2016/071947 WO2017046314A2 (en) 2015-09-18 2016-09-16 Improvement of expression and folding in the manufacturing process of cd-rap by using a cd-rap precursor protein

Publications (1)

Publication Number Publication Date
CA2998665A1 true CA2998665A1 (en) 2017-03-23

Family

ID=57223637

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2998665A Abandoned CA2998665A1 (en) 2015-09-18 2016-09-16 Improvement of expression and folding in the manufacturing process of cd-rap by using a cd-rap precursor protein

Country Status (8)

Country Link
US (2) US10660852B2 (https=)
EP (1) EP3350204A2 (https=)
JP (1) JP6976254B2 (https=)
CN (1) CN108602866A (https=)
AU (2) AU2016321884B2 (https=)
CA (1) CA2998665A1 (https=)
TW (1) TW201726712A (https=)
WO (1) WO2017046314A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3766356B1 (en) * 2018-03-16 2025-01-15 Eco-Geo Bio-Technology Company Limited Method to enhance the proteolysis efficiency of pepsin or trypsin
CN108410803B (zh) * 2018-03-28 2019-02-05 湖南源品细胞生物科技有限公司 一种诱导脂肪干细胞成软骨分化的培养方法和培养液
FR3092339B1 (fr) * 2019-02-05 2024-04-12 Michelin & Cie Cellule, notamment levure, resistante au phloroglucinol
CN113024675A (zh) * 2020-12-29 2021-06-25 山东第一医科大学(山东省医学科学院) 一种hb-nc4重组蛋白及其制备方法与应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL95495A (en) * 1989-08-29 1996-10-16 Hoechst Ag Fusion proteins their preparation and use
AU5705600A (en) * 1999-06-30 2001-01-22 Takeda Chemical Industries Ltd. Novel polypeptide and dna thereof
JP4579378B2 (ja) * 1999-06-30 2010-11-10 武田薬品工業株式会社 新規ポリペプチドおよびそのｄｎａ
EP1604693A1 (en) * 2004-06-09 2005-12-14 Scil Technology GmbH In situ forming scaffold, its manufacturing and use
CN102940878A (zh) 2006-10-06 2013-02-27 Scil技术股份有限公司 脊柱髓核植入物
EP2547700A1 (en) * 2010-03-17 2013-01-23 Universität Regensburg Peptides or antibodies which bind to melanoma inhibitory activity (mia) protein
BR112012027361A2 (pt) * 2010-04-27 2021-04-27 Scil Technology Gmbh formulação mia/cd-rap estável.

Also Published As

Publication number Publication date
EP3350204A2 (en) 2018-07-25
US10660852B2 (en) 2020-05-26
AU2016321884A1 (en) 2018-04-12
AU2021202110A1 (en) 2021-05-06
WO2017046314A2 (en) 2017-03-23
CN108602866A (zh) 2018-09-28
US20190046442A1 (en) 2019-02-14
JP6976254B2 (ja) 2021-12-08
JP2018527030A (ja) 2018-09-20
WO2017046314A3 (en) 2017-05-26
US20200268663A1 (en) 2020-08-27
AU2016321884B2 (en) 2021-01-07
TW201726712A (zh) 2017-08-01

Similar Documents

Publication Publication Date Title
AU2021202110A1 (en) Improvement of expression and folding in the manufacturing process of CD-RAP by using a CD-RAP precursor protein
CN114728078B (zh) 与分子连接的细胞外囊泡及其用途
Lipinski et al. Prdx4 limits caspase‐1 activation and restricts inflammasome‐mediated signaling by extracellular vesicles
EP4470619A2 (en) Extracellular vesicle-aso constructs targeting stat6
US20230018254A1 (en) Extracellular vesicles with antisense oligonucleotides targeting kras
MX2010011339A (es) Composiciones farmaceuticas de paclitaxel, analogos de paclitaxel o conjugados de paclitaxel, y metodos relacionados de preparacion y uso.
US20230193274A1 (en) Extracellular vesicles with stat3-antisense oligonucleotides
US20230132093A1 (en) Extracellular vesicle-nlrp3 antagonist
US20230002764A1 (en) Extracellular vesicle-aso constructs targeting cebp/beta
US11834517B2 (en) Branched peptides for enzymatic assembly and mitochondria drug delivery
US20200281854A1 (en) Branched peptides for enzymatic assembly and mitochondria drug delivery
WO2014194428A1 (en) Targeted heparan sulfatase compounds
JP2008510476A (ja) 生物学的材料からのｘｉｉｉ因子ポリペプチドの精製
JP2022552217A (ja) 脊髄損傷の治療のため及び／又は髄鞘再形成のためのペプチドの全身投与
US9670250B2 (en) Alpha-helical peptidomimetic inhibitors and methods using same
US20260027147A1 (en) Extracellular vesicle-aso constructs targeting cebp/beta
US12214076B2 (en) Drug delivery vehicles for atherosclerosis nanomedicine
US20240158441A1 (en) Branched peptides for enzymatic assembly and mitochondria drug delivery
HK40119027A (zh) 靶向CEBP/β的细胞外囊泡-ASO构建体
WO2015077317A1 (en) Compositions and methods for the purification and production of butyrylcholinesterase
JP2020026397A (ja) ＴｒｋＢアンタゴニストを含む医薬組成物

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210915

FZDE Discontinued

Effective date: 20240219